News Watch


A grant from the Melanoma Research Foundation powers the initial stages of the project.

View Article

Study shows nearly 50% reduction in benign lesions excised.

View Article

New synthetic small molecule aims to counter drug resistance in BRAF-mutated melanomas.

View Article

Immunotherapy, intralesional treatments, multidisciplinary care teams define rapidly-evolving multimodal approach.

View Article

Data shows that the overall rate of melanoma diagnosis rose sixfold over the last 4 decades at a time when melanoma mortality stayed relatively stable.

View Article

The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.

View Article

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

View Article

The addition of bempegaldesleukin to nivolumab did not significantly improve progression-free survival, objective response rate, or overall survival vs nivolumab alone in the frontline treatment of patients with unresectable or metastatic melanoma, missing the primary end points of the phase 3 PIVOT IO-001 trial.

View Article

Researchers at the University of California in San Diego have discovered extrafollicular skin cells that transform into antimicrobial fat cells and fight acne, according to a study published in Science Translational Medicine.

View Article

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

View Article